Investors Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) are heading into the 3rd quarter of this year on a positive note as the stock provided some gains of 313.46% over the past 6 months. More recently the stock is -0.46% over the past 5 trading days. Looking a bit further out the stock is -44.44% for the month and -15.02% for the quarter.
At the session level, shares of Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) moved -1.83% from the open. The most recent bid on the stock was registered at $2.15. Further, company shares have been seen trading -63.99% off of the 52 week high and 756.57% away from the 52 week low. Narrowing in further, the stock has been recently noted at -63.99% away from the 50 day high and 1.42% separated from the 50 day low.
Wall Street brokerage firms that regularly cover the stock have provided price targets and recommendations on Eleven Biotherapeutics, Inc. (NASDAQ:EBIO). According to First Call, the consensus price target for the company is $12.00. The consensus recommendation provided by analysts is currently 2.00. This number is based on a scale from 1 to 5. Analysts rating the company a 1 or 2 indicate a Buy recommendation. Analysts rating the company a 4 or 5 indicate a Sell recommendation. Analysts rating the company a 3 indicate a Hold recommendation.
The advice provided on this website is general advice only. It has been prepared without taking into account your objectives, financial situation or needs. Before acting on this advice you should consider the appropriateness of the advice, having regard to your own objectives, financial situation and needs. Where quoted, past performance is not indicative of future performance.